Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Active Crohn's Disease (APOLLO)
NCT02597829Phase 4Unknown
- Sponsor
- Shafran Gastroenterology Center
- Start
- Nov 2015
- Primary completion
- May 2018
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of certolizumab pegol in Crohn's disease, sponsored by Shafran Gastroenterology Center. Status: unknown.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02597829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597829.